Together, these data indicate that TREX1 loss activates a tumor intrinsic innate immune response, probably caused by an aberrant accumulation of chemotherapy-derived cytoplasmic DNAs, which lead to the decreased growth rate of drug-resistant cells. This evidence concerns the gene TREX1 and neoplasm.